Clinical Research Directory

Inclusion Criteria: * Current consent form signed * Capacity to give informed consent * Age range 18-65 (inclusive) * Diagnosis of MDD or bipolar depression and currently in a major depressive episode * Score of at least 29 on the MADRS (at least moderate depression) Exclusion Criteria: * Hypersensitivity to celecoxib, minocycline, tetracyclines, sulfonamides, aspirin, other NSAIDs, or any component of the formulation; previous asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs * History of myocardial infarction or current cardiac condition * Heptic impairment, heart failure, severe renal impairment, recent GI bleed, history of peptic ulcer disease, anemia or any other contraindication for celecoxib or minocycline * Poor CYP2C9 metabolizer * Currently taking medications that interact with celecoxib (digoxin, antihypertensives, diuretics, anticoagulant or anti-platelet treatment, including aspirin), or minocycline (isotretinoin, ergot alkaloids) without providing physicians approval * Use of herbs, drugs, or medications with anti-inflammatory or immunomodulatory properties (within 5 half-lives of starting celecoxib or minocycline treatment) * Unlikely to tolerate medication washout or the medication-free period following washout. * Participant considered at significant risk for suicide. * Electroconvulsive therapy (ECT) within 1 month * High potential for excessive drug/alcohol use during the treatment period (excluding nicotine or cannabis) * Significant active physical illness or neurological deficit that may affect brain functioning. * If participant is currently pregnant, breastfeeding, or planning to conceive during the course of study participation. * Need for medications that control mania.